Tacrolimus
We have built tacrolimus PK models following pediatric heart transplant for patients in Utah and across the US. Ongoing work is focused on testing our dosing decision support tool, defining the impact of genotype on tacrolimus PK, and identifying novel biomarkers that can be used to discriminate safe/effective dosing/exposures.
(Val)ganciclovir
Congenital cytomegalovirus (cCMV) infection poses significant risk for hearing loss and related outcomes in children. cCMV can be treated, however, current drugs/dosing regimens are associated with risk of toxicity, and the effective dose is poorly understood. Working with a clinical colleague, Dr. Albert Park, the Rower lab conducts clinical/translational research studies to optimize treatment of this patient population.
Cannabis
Cannabis access, use, and acceptance have increase substantially over the past decade, far outpacing research in the field. With its integration into the Center for Human Toxicology and access to rodent inhalation equipment within Dr. Chris Reilly's laboratory, the Rower lab is well-positioned to address many outstanding questions related to cannabis pharmacokinetics/pharmacodynamics. Of particular interest is the interplay of sex, age at initiation, and total cannabis exposure on neuromaturation.
Miscellaneous
The Rower lab has many other ongoing projects where they provide expertise to support ongoing clinical studies.
Among these are projects evaluating:
- The benefits of IV MgSO4 in pediatric asthma exacerbation
- Different strategies for using buprenorphine for low-dose induction that avoids precipitated withdrawal in the fentanyl era
- The pharmacokinetics of novel anticonvulsant medications in preclinical models.